Wealth Enhancement Advisory Services LLC Increases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 14.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,404 shares of the biopharmaceutical company's stock after purchasing an additional 1,838 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Alnylam Pharmaceuticals were worth $3,889,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $1,045,822,000. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $577,941,000. Capital Research Global Investors boosted its position in shares of Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after acquiring an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after acquiring an additional 1,245,195 shares in the last quarter. Finally, Marshall Wace LLP lifted its stake in Alnylam Pharmaceuticals by 496.6% during the fourth quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after purchasing an additional 315,182 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $3.26 during trading on Monday, hitting $326.09. The stock had a trading volume of 943,507 shares, compared to its average volume of 859,514. The firm has a market capitalization of $42.52 billion, a P/E ratio of -156.02 and a beta of 0.22. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $330.16. The company's 50-day moving average price is $288.10 and its 200 day moving average price is $264.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The firm had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same period in the previous year, the firm earned ($0.16) EPS. The firm's revenue was up 20.2% on a year-over-year basis. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the topic of a number of research analyst reports. Scotiabank raised their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a report on Monday, March 31st. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research report on Friday, March 21st. JPMorgan Chase & Co. lifted their price target on shares of Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the stock an "overweight" rating in a research note on Thursday, June 12th. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Finally, Morgan Stanley reduced their target price on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and twenty have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $340.00.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the transaction, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.20% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.